Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin for irritable bowel syndrome
IRCT20221211056775N1Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in irritable bowel syndrome (IBS) comparing Rifaximin with Placebo (2 arms). Primary endpoints: Quality of life and Clinical symptoms. Started Jan 2023; status: completed.
02
Drugs
rifaximin
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on IRCT20221211056775N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20221211056775N1.